Ayurveda wellness brand Kapiva secured $60 million in Series D funding, backed by 360 ONE Asset, Vertex Growth, Vertex Ventures, 3one4 Capital, and Fireside Ventures. Kapiva raised $60 million in Series D funding, with $28 million in primary capital and $32 million in secondary share sales.

The transaction enabled Fireside Ventures, one of the brand’s early backers, to exit. The round, co-led by 360 ONE Asset and Vertex Growth, also saw strong support from Vertex Ventures and 3one4 Capital. With this close, Kapiva has raised nearly $90 million since its inception.

The Ayurveda wellness brand will utilize the funds for research and development, manufacturing, brand building, and marketing. In addition, Kapiva plans to expand its health-tech platform, focusing on chronic condition management and personalized care.

International growth remains a priority, with subsidiaries already established in the US, UK, and UAE. Currently, overseas sales account for 5–10 percent of the brand’s revenue, and the company anticipates this share will increase.

Rapid Revenue Growth of Kapiva

Founded in 2015 by Ameve Sharma and Shrey Badhani, Kapiva has grown its presence across India and abroad. The Ayurveda wellness brand now operates at an annual revenue run rate of about INR 550 crore, up from Rs 350 crore in FY25. Over the past three years, it has recorded more than 80 percent year-on-year growth. Although slightly EBITDA negative, Kapiva expects to reach profitability in the coming quarter.

Meanwhile, the Ayurvedic and herbal wellness market in India is experiencing rapid growth. Some reports estimate that the market will expand at a rate of ~17-19 percent CAGR over the coming years. The wellness trend, especially post-COVID, has accelerated significantly. Investors want exposure to that tailwind.

Direct-to-consumer models enable better margins, deeper customer insights, and stronger brand control. When combined with offline distribution, it gives reach. Kapiva’s hybrid model increases resilience. Investors like that balanced risk.

Consumers are increasingly preferring “natural,” “herbal,” and “organic” products, as well as showing an increasing awareness of preventative wellness. Brands that can effectively combine authenticity, modernity, and strong branding are likely to succeed. Investors see Kapiva positioning well here.

Expanding Distribution and Product Range

Kapiva products span over 100 SKUs, including supplements, gummies, capsules, skincare, and specialized formulations for diabetes, hypertension, liver health, and sports nutrition. The Ayurveda wellness brand has expanded its offline distribution network to 40,000 stores across India, while maintaining a strong presence through its website and e-commerce channels.

Kapiva competes with Innovacare, Gynoveda, and Wellbeing Nutrition in the rapidly growing herbal and Ayurvedic wellness sector. However, there is still considerable scope for these companies, as the demand for wellness products for daily health, including energy, digestion, hormonal balance, and skincare, is on the rise, not only for disease prevention.

Kapiva addresses many of these wellness niches that traditional players may overlook or serve poorly. Consumers want preventative health and wellbeing; Kapiva aligns with that.

As customers become more discerning, there is an increasing expectation for higher standards, including quality inputs, more rigorous testing, and credible supply chains. Small Ayurvedic brands often lack the capability for larger-scale research and development (R&D) or modern manufacturing; Kapiva is raising funds to strengthen these areas.

Stay ahead of the curve and follow IndiaTechDesk on Facebook, Twitter and Linkedin for in-depth news of market trends, funding updates, and regulatory changes affecting startups in India.